GYRE

$4.44-6.13%visit website

GYRE THERAPEUTICS, INC.

Market Cap

$495M

Live price × SEC shares (Aug 1, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

2.57

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

4.1

TTM to Jun 2026 · revenue

P/B

4.6

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	30,564	37,195	22,519	29,105	119,383
Cost of revenue	1,628	1,743	1,227	2,209	6,807
Gross profit	28,936
Research & development	2,363	4,815	6,738
Selling, general & administrative				7,862
Total operating expenses	22,011	40,750	31,874	43,463	138,098
Operating income	6,925	118	(9,355)	(14,363)	(16,675)
Pretax income	7,629	(66)	(9,237)	(14,434)	(16,108)
Income tax	1,693	1,300	621	(164)	3,450
Net income	5,936	(1,320)	(18,579)	(14,270)	(28,233)
EPS (basic) ($)	0.04		(0.10)	(0.12)	(0.20)
EPS (diluted) ($)	0.03		(0.10)	(0.12)	(0.21)
Weighted avg. shares (basic)	90,850		91,317	100,638
Weighted avg. shares (diluted)	103,972		91,345	100,638

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 7, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 61 more quarters, back to Jun 2010, with Tormere Pro.

Corporate Events (8-K)

19 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Oct 22, 2026 accepted 8:01 PM ET	5.02Officer / director change	Document SEC ↗
Sep 1, 2026 accepted 1:00 PM ET	7.01Reg FD disclosure	Document SEC ↗
Aug 26, 2026 accepted 1:00 PM ET	7.01Reg FD disclosure	Document SEC ↗
Aug 7, 2026 accepted 12:00 PM ET	2.02Earnings release	Document SEC ↗
Jul 16, 2026 accepted 8:35 PM ET	5.02Officer / director change7.01Reg FD disclosure	Document SEC ↗
Jul 15, 2026 accepted 9:09 PM ET	8-K/A 2.02Earnings release	Document SEC ↗
Jun 16, 2026 accepted 10:30 AM ET	5.07Shareholder vote	Document SEC ↗
Jun 2, 2026 accepted 10:09 AM ET	7.01Reg FD disclosure	Document SEC ↗
May 14, 2026 accepted 9:25 PM ET	7.01Reg FD disclosure	Document SEC ↗
May 12, 2026 accepted 9:03 PM ET	7.01Reg FD disclosure	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

77%

W/W +35.4pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-06-18	2026-06-22	Ye Weiguo	Chief Operating Officer	Sale	3,000	$6.35	$19K	700.0K	View
2026-06-10	2026-06-22	Ye Weiguo	Chief Operating Officer	Sale	11.4K	$6.22	$71K	700.0K	View
2026-06-09	2026-06-22	Ye Weiguo	Chief Operating Officer	Sale	17.5K	$6.14	$107K	700.0K	View
2026-06-11	2026-06-15	Ye Weiguo	Chief Operating Officer	Sale	2,800	$6.17	$17K	700.0K	View
2026-06-05	2026-06-08	Ye Weiguo	Chief Operating Officer	Sale	15.4K	$6.40	$99K	700.0K	View